Literature DB >> 10223250

Lymphocyte subpopulations in patients with multiple primary tumors.

E Robinson1, R Segal, L Struminger, D Faraggi, R El'ad-Yarum, T Mekori.   

Abstract

BACKGROUND: Cancer patients with single tumors live longer today due to earlier detection and improved treatment methods. For this reason, the authors see more patients who develop a second primary tumor. The etiology of the second tumor can be the same as the first, whether treatment-induced or unknown. The prognoses of these patients usually depend on the behavior of the second tumor.
METHODS: The authors investigated the lymphocyte subset in 88 of the more than 750 patients listed in the tumor registry at their treatment center who had at least one carcinoma of the breast or colon and a second primary of the same or another site. Mononuclear cells were obtained from heparinized blood by the standard fractionation Hypaque gradient centrifugation technique. Helper and suppressor cells were identified by using three murine monoclonal antibodies: CD3 for mature T lymphocytes, CD4 for helper inducer cells, and CD8 for suppressor cytotoxic cells. T-cell subset distribution was evaluated with flow cytometry.
RESULTS: Most values of CD3, CD4, and CD4/CD8 were lower in patients than in healthy controls. The values of CD4 and CD4/CD8 were lower in patients who had a second tumor in the colon rather than in the breast.
CONCLUSIONS: As tumors in patients with a second primary sometimes recur or the patient develops a third primary, the authors are prospectively following their patients to see whether those with immunosuppression have a greater tendency to develop recurrent disease or a third primary.

Entities:  

Mesh:

Year:  1999        PMID: 10223250     DOI: 10.1002/(sici)1097-0142(19990501)85:9<2073::aid-cncr26>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.

Authors:  Hongjin Chu; Fengcai Du; Lixin Jiang; Zhixin Wang; Zhaohua Gong; Peiwen Lian; Peng Li; Jian Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-19

2.  Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Authors:  Leonard Christopher Schmeel; Frederic Carsten Schmeel; Christoph Coch; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

3.  Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients.

Authors:  Yitao Gong; Zhiyao Fan; Guopei Luo; Qiuyi Huang; Yunzhen Qian; He Cheng; Kaizhou Jin; Quanxing Ni; Xianjun Yu; Chen Liu
Journal:  Cancer Manag Res       Date:  2020-08-03       Impact factor: 3.989

4.  Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer.

Authors:  Liangrong Shi; Qi Zhou; Jun Wu; Mei Ji; Guojun Li; Jingting Jiang; Changping Wu
Journal:  Cancer Immunol Immunother       Date:  2012-06-07       Impact factor: 6.968

Review 5.  Cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis.

Authors:  Xiang Wang; Song Tang; Xiang Cui; Jinwei Yang; Chunyu Geng; Cong Chen; Ning Zhou; Yumin Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.